力大圖書
力 大 醫 學 圖 書 網          www.leaderbook.com.tw          歡迎使用  國民旅遊卡!!
帳號 密碼
加入會員 | 首頁 | 服務 | 行銷回應 | 代訂 | 購物車 | 預訂清單
Search
      圖書搜尋

 - 進階搜尋
  代訂書籍
  加購書籍專區
Classes
      圖書類別
運費(購買金額未滿NT$1000,請自行加上運費)
文化幣使用須知
台灣Pay使用須知
國民旅遊卡使用須知
購買注意事項與營業時間
力大圖書出版品
橘井文化系列叢書
免疫風濕科
內分泌科
內科(家醫科及實証醫學)
婦產科
眼科
病理科(檢驗科)
外科
耳鼻喉科(聽力和語言治療)
泌尿科
胸腔內科(重症醫學)
胸腔外科
腫瘤科(血液科)
放射腫瘤科
麻醉科(疼痛科)
獸醫科
神經外科
神經內科
小兒科
心臟內科
心臟血管外科
急診科
感染科
放射線科
核子醫科
牙科(口腔外科)
皮膚科(醫學美容)
精神科
胃腸科
骨科
腎臟科
整形外科
藥劑科
護理科
復健科(運動醫學)
食品營養
限量特價專區
解剖學(組織學)
基礎醫學科
醫學模型
醫學掛圖
SPRINGER庫存出清專區
 
 
 
-■ ■ ■ ■ ■ ■ 圖 書 介 紹
Advances in Combination Therapy for Asthma and COPD 2012(已絕版)
-胸腔內科(重症醫學)
- 編號: 0-000000000000000470727027
- 作者:Jan Lotvall
- 原價-5115    - (熱賣價)3960      - 節省 ↓23%
- 加入購物車
推薦指數:
- 內容介紹
Advances in Combination Therapy for Asthma and COPD
Jan Lotvall (Editor)
ISBN: 978-0-470-72702-7
Hardcover
364 pages
Pub Date : 2012

Introduction 1

1.2 Pulmonary function abnormalities in asthma and COPD 3

1.3 Risk factors for asthma and COPD 5

1.4 Cellular inflammation in asthma and COPD 8

1.5 Distribution and consequences of inflammation in asthma and COPD 9

1.6 Patterns of epithelial injury in asthma and COPD 10

1.7 Airway hyperresponsiveness 10

1.8 Beta-receptor blockers 10

1.9 Differential diagnosis of asthma and COPD 11

1.10 Overlap syndrome 12

1.11 Conclusion 12

References 13

2 Glucocorticoids: pharmacology and mechanisms 16
Peter J. Barnes

2.1 Introduction 16

2.2 Chemical structures 16

2.3 The molecular basis of inflammation 17

2.4 Cellular effects of glucocorticoids 19

2.5 Glucocorticoid receptors 20

2.6 Glucocorticoid activation of gene transcription 22

2.7 Suppression of inflammatory genes 23

2.8 Steroid resistance 29

2.9 Interaction with 2-adrenergic receptors 32

2.10 Conclusions 33

References 33

3 Inhaled corticosteroids: clinical effects in asthma and COPD 38
Paul M. O’Byrne and Desmond M. Murphy

3.1 Introduction 38

3.2 Anti-inflammatory activity of corticosteroids 38

3.3 Routes of administration 39

3.4 Absorption and fate of corticosteroids 41

3.5 Currently available inhaled corticosteroids 41

3.6 Efficacy in asthma 43

3.7 Efficacy in COPD 44

3.8 Side effects of ICS 46

3.9 Conclusions 49

References 49

4 LABAs: pharmacology, mechanisms and interaction with anti-inflammatory treatments 53
Gary P. Anderson

4.1 Galenical forms of LABAs: formulations, isomers, enantiomers, diasteriomers and salts 55

4.2 Absolute and functional 2-adrenoceptor selectivity 56

4.3 Cellular organization of receptor clusters: functional structure of the 2-adrenoceptor and mode of signalling 58

4.4 Dimers and oligomers: homo- and heterodimerism/oligoism 60

4.5 Pharmacogenomics of the 2-adrenoceptor and adenylate cyclase polymorphism in relation to LABAs 61

4.6 Understanding the ‘reassertion’ paradox, ‘exosites’ and relative speed of onset: the membrane diffusion microkinetic model of LABA action 61

4.7 Regulation and desensitization 63

4.8 Full versus partial agonism (pharmacological efficacy) 64

4.9 Beta-blockers not LABAs? 67

4.10 Non-receptor-mediated effects? 68

4.11 Biochemical basis of functional antagonism and its critical role in LABA action in disease and exacerbations 68

4.12 Molecular cooperativity between LABAs and steroids 69

4.13 Perspective 73

References 73

5 Long- and ultra-long-acting 2-agonists 81
Mario Cazzola and Maria Gabriella Matera

5.1 Introduction 81

5.2 Long-acting 2-agonists 82

5.3 Novel ultra-long-acting 2-agonists 86

5.4 Conclusion 95

References 95

6 The safety of long-acting beta-agonists and the development of combination therapies for asthma and COPD 102
Victor E. Ortega and Eugene R. Bleecker

6.1 Introduction 102

6.2 Asthma-related mortality and beta-agonist exposure 103

6.3 Long-acting beta-agonists and increased asthma-related mortality 105

6.4 Safety and efficacy of LABA therapy in asthma: retrospective analyses 107

6.5 Efficacy of LABA therapy as a component of combination therapy with ICS for the management of asthma 110

6.6 Scientific basis of the beneficial and adverse effects of beta-agonist therapy: in vitro data and the beta-agonist paradox 113

6.7 Conclusions regarding the safety of LABA therapy as a component of combination therapy with ICS for the management of asthma 114

6.8 Beta-agonist therapy and adverse events in COPD 115

6.9 Safety and efficacy of LABA therapy in the management of COPD: the clinical evidence 116

6.10 Role of LABA therapy as a component of combination therapy with ICS for the management of COPD 117

6.11 Conclusions regarding the safety of LABA therapy as a component of combination therapy for the management of COPD 120

6.12 Pharmacogenetics of LABAs and combination therapy 120

6.13 Safety and efficacy of LABA therapy and the development of combination therapies for the management of asthma and COPD 126

6.14 Summary and future directions 127

Acknowledgement 128

References 128

7 Inhaled combination therapy with glucocorticoids and long-acting 2-agonists in asthma and COPD, current and future perspectives 135
Jan Lötvall

7.1 Pharmacological management guidelines of asthma and COPD 135

7.2 Steroid treatment in asthma 136

7.3 Effects of adding LABA to inhaled glucocorticoids in asthma 137

7.4 Steroid treatment in COPD 140

7.5 Effects of LABAs in COPD 140

7.6 Combination inhalers versus two separate inhalers for inhaled GCS and LABAs 141

7.7 Regular treatment alone versus additional formoterol-containing combinations as reliever therapy 143

7.8 Currently available combination inhalers 145

7.9 Upcoming and alternative combinations of inhaled GCS and LABAs 146

7.10 Future of combined inhalation therapy in respiratory disease 148

References 149

8 Novel anti-inflammatory treatments for asthma and COPD 154
Paul A. Kirkham, Gaetano Caramori, K. Fan Chung and Ian M. Adcock

8.1 Introduction 154

8.2 Current asthma and COPD therapies 158

8.3 The need for new therapies 160

8.4 Improving current therapies 162

8.5 Targeting chemokines and their receptors in asthma and COPD 166

8.6 Targeting T-cell-derived and proinflammatory cytokines in asthma and COPD 169

8.7 Targeting adhesion molecules in asthma and COPD 172

8.8 Growth factor blockers in asthma and COPD 173

8.9 Mucous cells, submucosal glands and mucus production in asthma and COPD 173

8.10 Infections in asthma and COPD 174

8.11 Intracellular signalling pathways 175

8.12 Inhibition of transcription factors in asthma and COPD 178

8.13 Antioxidants in asthma and COPD 181

8.14 Immunomodulation and anti-allergy treatments in asthma and COPD 182

8.15 Conclusions 185

Acknowledgements 186

References 186

9 Novel biologicals alone and in combination in asthma and allergy 203
Sharmilee M. Nyenhuis and William W. Busse

9.1 Introduction 203

9.2 Targets of therapy 204

9.3 Interleukin-4 204

9.4 Interleukin-5 207

9.5 Interleukin-13 211

9.6 Tumor necrosis factor-212

9.7 Immunoglobulin E 215

9.8 DNA vaccines 220

9.9 Future directions 222

9.10 Conclusion 224

References 225

10 Anti-infective treatments in asthma and COPD 232
Jonathan D.R. Macintyre and Sebastian L. Johnston

10.1 Introduction 232

10.2 Current guidelines 234

10.3 Acute exacerbations of asthma 236

10.4 Increased susceptibility to infection in asthmatics 236

10.5 Role of atypical bacteria in asthma 237

10.6 Role of viruses in asthma exacerbations 244

10.7 Anti-infectives in COPD exacerbations 250

10.8 Use of antibiotics in stable COPD 256

10.9 Role of vaccination 257

10.10 Conclusion 259

References 260

11 Long-acting muscarinic antagonists in asthma and COPD 268
M. Diane Lougheed, Josuel Ora and Denis E. O’Donnell

11.1 Introduction 268

11.2 Innervation of the airways 268

11.3 Cholinergic mechanisms in asthma and COPD 270

11.4 Role of long-acting anticholinergic bronchodilators in obstructive lung disease 271

11.5 Summary 287

References 288

12 Phosphodiesterase inhibitors in obstructive lung disease 296
Jan Lötvall and Bo Lundbä ck

12.1 Introduction 296

12.2 Phosphodiesterase enzymes 297

12.3 Different pharmacological agents blocking PDE4 298

12.4 Biological effects of PDE4 inhibition, preclinical information 300

12.5 Clinical effects of PDE4 inhibition in COPD 302

12.6 Effects of PDE4 inhibitors on systemic processes in COPD 304

12.7 Side effects of PDE4 inhibitors 304

12.8 PDE4 inhibitors in COPD management plans 305

12.9 Future prospects with PDE4 inhibitors in obstructive airways disease 305

12.10 Summary 306

References 306

13 Biological therapies in development for COPD 311
J. Morjaria and R. Polosa

13.1 Introduction 311

13.2 Inflammatory cells involved in the pathogenesis of COPD 312

13.3 Cytokines and chemokines in COPD 315

13.4 Development of biological agents in COPD 320

13.5 Conclusions 323

References 323

14 ‘Triple therapy’ in the management of COPD: inhaled steroid, long-acting anticholinergic and long-acting 2-agonist 333
Ronald Dahl

14.1 Introduction 333

14.2 Long-acting inhaled anticholinergic (LAMA) and 2-agonist (LABA) bronchodilators 333

14.3 Treatment strategies for COPD 334

14.4 Inhaled corticosteroids and COPD 334

14.5 Combination treatment with ICS, LAMA and LABA: ‘triple therapy’ 335

14.6 Extracted data from TORCH and UPLIFT studies 337

14.7 Conclusions 340

References 341

Index 343


Share This Printer-ready version


歡迎使用國民旅遊卡
歡迎使用國民旅遊卡
其他相關書藉
  請輸入關鍵字
相 關 書 藉
Baum's Textbook of Pulmonary Diseases: Hardbound
- 胸腔內科(重症醫學)
- 作者:James D Crapo MD
Review of Sleep Medicine 4/E 2018
- 胸腔內科(重症醫學)
- 作者:Alon Y. Avidan MD MPH
Specialty Imaging: HRCT of the Lung Anatomic Basis, Imaging Features, Differential Diagnosis + Webstie 2009
- 胸腔內科(重症醫學)
- 作者:Jud W Gurney MD
Pilbeam's Mechanical Ventilation: Physiological and Clinical Applications 7/E 2020
- 胸腔內科(重症醫學)
- 作者: J M Cairo PhD RRT
PDxMD Respiratory Medicine
- 胸腔內科(重症醫學)
- 作者:PDxMD
--- more
[ 積點系統 ]
您已經累積多少點數您知道嗎?別忘了登錄會員,察看您的點數,獎品就等您來拿喲!
[ 訂購辦法 ]
您還不知道要在本網站如何購物嗎?我們將會提供給您訂購的方法及購物相關資訊喲!讓您彈指間取得想要的書藉。
 
      圖書搜尋         本網站購物機制使用 SSL+ 加密技術,請放心購物 Safe100%

| 加入會員 | 回首頁 | 服務中心 | 行銷回應 | 購物須知 | 會員條款 | 關於力大 | 權益申明 | 合作對象 |

本站內容為 力大圖書有限公司 所有,未經同意,請勿任意引用轉載
電話:(02)2733-2592 傳真:(02)2732-5743 E-mail:service@leaderbook.com.tw
力大圖書:台北市和平東路二段90巷2號4樓之2  台中分店:臺中榮總婦幼大樓1F
Copyright 2002-2010 LeaderBook CO.,LTD All rights reserved.